Fate Therapeutics FATE Cash Flow Statement (2012-2026)

NASDAQ FATE
$2.11 +0.05 (+2.43%)
As of: Oct 21, 2026 · 9:47 AM EDT
Reported Financials

Fate Therapeutics Quarterly Cash Flow Statement

Periods 56 quarters
Latest Jun 2026

Fate Therapeutics reported cash from operations of -$23.40M and free cash flow of -$23.48M for the quarter ended Jun 2026, up 4.8% year over year. This cash flow statement covers 56 quarters of results from Sep 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-43.31M-68.62M-65.69M-76.11M-83.56M-56.36M-18.88M-52.76M-45.17M-44.12M-48.00M-38.43M-47.68M-52.15M-37.62M-34.07M-32.25M-32.37M-31.21M-30.16M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
1.11M1.29M1.09M-0.33M0.78M1.13M7.20M
Depreciation & Amortization (CF)Dep. & Amort.
1.52M2.26M2.76M2.96M3.19M4.88M4.19M4.47M4.74M4.90M4.82M4.72M4.61M4.85M3.33M3.28M3.23M3.06M2.92M2.78M
Share-based CompensationStock Comp.
13.54M14.59M19.33M20.54M19.47M19.39M10.98M12.90M10.10M9.48M10.98M9.63M11.77M9.12M7.38M7.15M4.86M5.53M3.93M3.52M
Gains from Sales and DivestituresGains Divest
-0.94M-0.05M
Other non-cash itemsOther Non-Cash
-11.03M-0.46M-8.36M-5.88M-0.89M-5.18M-1.72M-0.39M-1.05M0.65M1.39M-1.56M0.01M-0.67M-0.28M0.07M0.09M-0.13M0.08M0.58M
Change in Working Capital
Change in ReceivablesChange Receivables
-2.99M1.37M5.17M-0.72M-2.90M28.26M-24.98M-10.67M-1.30M0.29M-0.97M0.19M2.48M-0.59M-1.13M-1.01M-0.71M0.23M-0.21M0.00M
Change in Accured ExpensesChange Accured Exp.
6.74M-10.38M-3.49M4.08M10.28M3.39M-20.39M-4.37M-2.28M-1.89M-4.51M0.32M1.87M0.66M-9.83M0.48M-0.55M0.87M-5.77M1.26M
Change in Other Operating AssetsOther Assets Change
0.25M1.13M2.41M5.73M2.79M7.41M-11.90M-4.08M1.47M1.64M-4.57M3.49M-4.22M0.06M-3.93M0.79M-1.03M-1.01M-0.13M-0.52M
Change in Other Operating LiabilitiesOther Liabilities Change
-5.85M-7.50M-3.50M6.29M-3.75M-5.42M-40.49M0.19M-0.82M-0.43M-0.53M-0.16M-0.21M-0.18M-0.21M0.00M0.38M0.20M-0.58M
Other Working Capital ChangesOther WC Changes
0.20M-0.01M0.05M0.24M0.27M0.27M0.34M0.33M0.37M0.37M0.41M0.43M0.48M3.10M0.61M0.64M0.69M0.59M0.53M0.59M
Cash from OperationsCash from Ops.
-33.38M-70.29M-64.61M-53.16M-55.05M-75.39M-28.86M-28.49M-38.27M-36.64M-33.35M-32.31M-29.42M-27.80M-33.81M-24.59M-24.37M-23.31M-30.82M-23.40M
Investing Activities
Capital ExpendituresCapex
14.74M18.37M10.08M10.13M8.68M6.68M3.21M2.20M0.57M0.18M0.09M0.05M0.50M0.10M1.20M1.36M2.20M1.19M0.24M0.08M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.00M0.24M
Change in Property, Plant and EquipmentChange in PP&E
-14.74M-18.37M-10.08M-10.13M-8.68M-6.68M-3.21M-2.20M-0.57M-0.18M-0.09M-0.05M-0.50M-0.10M-1.20M-1.36M-2.20M-0.96M-0.24M-0.08M
Purchase of InvestmentsInvestments Purchased
165.47M173.45M132.17M63.95M101.58M107.10M114.45M92.26M102.13M49.97M86.34M128.67M64.74M38.01M48.62M50.81M57.98M37.73M28.73M58.35M
Sale and Maturity of InvestmentsInvestments Sold
258.16M263.09M135.22M114.37M190.63M166.89M127.00M127.63M127.50M95.50M103.74M75.34M90.70M60.92M92.49M71.64M81.45M66.32M52.56M72.98M
Cash from Investing ActivitiesCash from Investing
77.96M71.28M-7.03M40.29M80.38M53.11M9.34M33.17M24.81M45.35M17.31M-53.37M25.46M22.82M42.67M19.59M21.27M27.63M23.59M14.56M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Non-Current Debt
Net Debt Issuances and RepaymentsNet Debt Issuance
Change in Capital Stock
Common Stock IssuedStock Issued
28.62M-17.23M2.80M3.41M1.49M1.52M0.21M0.06M-0.18M95.49M-0.67M
Net Shares Issued and RepurchasedNet Shares Issued
28.62M-17.23M2.80M3.41M1.49M1.52M0.21M0.06M-0.18M95.49M-0.67M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
28.62M-17.23M2.80M3.41M1.49M1.52M0.21M0.06M-0.18M95.49M-0.67M
Other financing activitiesOther financing
3.13M
Cash from Financing ActivitiesCash from Financing
7.94M3.42M2.80M3.41M1.49M1.52M0.21M0.06M-0.18M95.49M1.27M3.13M1.33M2.48M1.69M
Additional items
Change in Cash
52.53M4.40M-68.84M-9.47M26.82M-20.76M-19.31M4.73M-13.47M8.54M79.45M-84.41M-3.96M-1.85M8.86M-3.67M-0.63M6.01M-7.24M-7.14M
Ending Cash Balance
Free Cash FlowFCF
-48.11M-88.66M-74.70M-63.29M-63.72M-82.07M-32.07M-30.69M-38.84M-36.82M-33.44M-32.36M-29.91M-27.90M-35.01M-25.95M-26.58M-24.51M-31.06M-23.48M
Net Cash FlowNCF
52.53M4.40M-68.84M-9.47M26.82M-20.76M-19.31M4.73M-13.47M8.54M79.45M-84.41M-3.96M-1.85M8.86M-3.67M-0.63M6.01M-7.24M-8.84M
Interest Paid

Fate Therapeutics Cash Flow Statement API

Pull Fate Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=FATE&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY